U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C19H19N3O3
Molecular Weight 337.3725
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of VOXELOTOR

SMILES

CC(C)N1N=CC=C1C2=NC=CC=C2COC3=C(C=O)C(O)=CC=C3

InChI

InChIKey=FWCVZAQENIZVMY-UHFFFAOYSA-N
InChI=1S/C19H19N3O3/c1-13(2)22-16(8-10-21-22)19-14(5-4-9-20-19)12-25-18-7-3-6-17(24)15(18)11-23/h3-11,13,24H,12H2,1-2H3

HIDE SMILES / InChI
Molecular Formula C19H19N3O3
Molecular Weight 337.3725
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Approval Year

Unknown
86413
Substance Class Chemical
Created
by admin
on Sat Dec 16 09:56:00 UTC 2023
Edited
by admin
on Sat Dec 16 09:56:00 UTC 2023
Record UNII
3ZO554A4Q8
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
VOXELOTOR
INN  
USAN   INN  
Official Name English
VOXELOTOR [MI]
Common Name English
VOXELOTOR [ORANGE BOOK]
Common Name English
VOXELOTOR [USAN]
Common Name English
OXBRYTA
Brand Name English
BENZALDEHYDE, 2-HYDROXY-6-((2-(1-(1-METHYLETHYL)-1H-PYRAZOL-5-YL)-3-PYRIDINYL)METHOXY)-
Systematic Name English
GTX-011
Code English
2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY) BENZALDEHYDE
Systematic Name English
GBT440
Code English
Voxelotor [WHO-DD]
Common Name English
GBT-440
Code English
voxelotor [INN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C78275
Created by admin on Sat Dec 16 09:56:01 UTC 2023 , Edited by admin on Sat Dec 16 09:56:01 UTC 2023
EU-Orphan Drug EU/3/16/1769
Created by admin on Sat Dec 16 09:56:01 UTC 2023 , Edited by admin on Sat Dec 16 09:56:01 UTC 2023
FDA ORPHAN DRUG 499715
Created by admin on Sat Dec 16 09:56:01 UTC 2023 , Edited by admin on Sat Dec 16 09:56:01 UTC 2023
Code System Code Type Description
USAN
EF-140
Created by admin on Sat Dec 16 09:56:01 UTC 2023 , Edited by admin on Sat Dec 16 09:56:01 UTC 2023
PRIMARY
DRUG CENTRAL
5356
Created by admin on Sat Dec 16 09:56:01 UTC 2023 , Edited by admin on Sat Dec 16 09:56:01 UTC 2023
PRIMARY
NCI_THESAURUS
C152089
Created by admin on Sat Dec 16 09:56:01 UTC 2023 , Edited by admin on Sat Dec 16 09:56:01 UTC 2023
PRIMARY
DAILYMED
3ZO554A4Q8
Created by admin on Sat Dec 16 09:56:01 UTC 2023 , Edited by admin on Sat Dec 16 09:56:01 UTC 2023
PRIMARY
CAS
1446321-46-5
Created by admin on Sat Dec 16 09:56:01 UTC 2023 , Edited by admin on Sat Dec 16 09:56:01 UTC 2023
PRIMARY
WIKIPEDIA
Voxelotor
Created by admin on Sat Dec 16 09:56:01 UTC 2023 , Edited by admin on Sat Dec 16 09:56:01 UTC 2023
PRIMARY
FDA UNII
3ZO554A4Q8
Created by admin on Sat Dec 16 09:56:01 UTC 2023 , Edited by admin on Sat Dec 16 09:56:01 UTC 2023
PRIMARY
LACTMED
Voxelotor
Created by admin on Sat Dec 16 09:56:01 UTC 2023 , Edited by admin on Sat Dec 16 09:56:01 UTC 2023
PRIMARY
INN
10454
Created by admin on Sat Dec 16 09:56:01 UTC 2023 , Edited by admin on Sat Dec 16 09:56:01 UTC 2023
PRIMARY
SMS_ID
100000176019
Created by admin on Sat Dec 16 09:56:01 UTC 2023 , Edited by admin on Sat Dec 16 09:56:01 UTC 2023
PRIMARY
PUBCHEM
71602803
Created by admin on Sat Dec 16 09:56:01 UTC 2023 , Edited by admin on Sat Dec 16 09:56:01 UTC 2023
PRIMARY
DRUG BANK
DB14975
Created by admin on Sat Dec 16 09:56:01 UTC 2023 , Edited by admin on Sat Dec 16 09:56:01 UTC 2023
PRIMARY
RXCUI
2265678
Created by admin on Sat Dec 16 09:56:01 UTC 2023 , Edited by admin on Sat Dec 16 09:56:01 UTC 2023
PRIMARY
EPA CompTox
DTXSID801027954
Created by admin on Sat Dec 16 09:56:01 UTC 2023 , Edited by admin on Sat Dec 16 09:56:01 UTC 2023
PRIMARY
MERCK INDEX
m12211
Created by admin on Sat Dec 16 09:56:01 UTC 2023 , Edited by admin on Sat Dec 16 09:56:01 UTC 2023
PRIMARY
Related Record Type Details
Structure of VOXELOTOR
CUMULATIVE EXCRETION
URINE
Structure of VOXELOTOR
EXCRETED UNCHANGED
FECAL
CYTOCHROME P450 3A5
METABOLIC ENZYME -> SUBSTRATE
In vitro metabolism studies involving recombinant enzymes indicated that CYP3A4, CYP1A1, CYP3A5, CYP2C9, CYP2C19 and CYP2B6 were responsible for the oxidative metabolism of voxelotor.
CYTOCHROME P450 1A1
METABOLIC ENZYME -> SUBSTRATE
In vitro metabolism studies involving recombinant enzymes indicated that CYP3A4, CYP1A1, CYP3A5, CYP2C9, CYP2C19 and CYP2B6 were responsible for the oxidative metabolism of voxelotor.
CYTOCHROME P450 2C9
METABOLIC ENZYME -> SUBSTRATE
In vitro metabolism studies involving recombinant enzymes indicated that CYP3A4, CYP1A1, CYP3A5, CYP2C9, CYP2C19 and CYP2B6 were responsible for the oxidative metabolism of voxelotor.
CYTOCHROME P450 3A4
METABOLIC ENZYME -> SUBSTRATE
MAJOR
CYTOCHROME P450 2C19
METABOLIC ENZYME -> SUBSTRATE
In vitro metabolism studies involving recombinant enzymes indicated that CYP3A4, CYP1A1, CYP3A5, CYP2C9, CYP2C19 and CYP2B6 were responsible for the oxidative metabolism of voxelotor.
CYTOCHROME P450 3A4
METABOLIC ENZYME -> INHIBITOR
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
CYTOCHROME P450 2B6
METABOLIC ENZYME -> SUBSTRATE
In vitro metabolism studies involving recombinant enzymes indicated that CYP3A4, CYP1A1, CYP3A5, CYP2C9, CYP2C19 and CYP2B6 were responsible for the oxidative metabolism of voxelotor.
Structure of VOXELOTOR
CUMULATIVE EXCRETION
FECAL
DEOXYHEMOGLOBIN S
TARGET->INHIBITOR OF AGGREGATION
BINDS DEOXYHEMOGLOBIN S WITH 1:1 STOICHIOMETRY; BLOOD:PLASMA RATIO 15:1
Structure of VOXELOTOR
EXCRETED UNCHANGED
URINE
Related Record Type Details
Structure of 2-HYDROXY-6-((2-(2-(2-HYDROXY-1-METHYL-ETHYL)PYRAZOL-3-YL)-3-PYRIDYL)METHOXY)BENZALDEHYDE
METABOLITE -> PARENT
FECAL; URINE
Structure of 2,6-DIHYDROXYBENZALDEHYDE
METABOLITE -> PARENT
FECAL; URINE
Structure of 2-HYDROXY-6-((2-(2-ISOPROPYLPYRAZOL-3-YL)-3-PYRIDYL)METHOXY)BENZOIC ACID
METABOLITE -> PARENT
FECAL; URINE
Structure of 2-(1-(1-METHYLETHYL)-1H-PYRAZOL-5-YL)-3-PYRIDINEMETHANOL
METABOLITE -> PARENT
FECAL; URINE
Related Record Type Details
Structure of VOXELOTOR
ACTIVE MOIETY
Official Title: A Phase I Randomised, Placebo-controlled, Double-blind, Single and Multiple Ascending Dose Study of the Tolerability and Pharmacokinetics of GBT440 in Healthy Subjects and Patients With Sickle Cell Disease Purpose : The purpose of this study is to assess the safety, tolerability, pharmacokinetic, and pharmacodynamic effects of GBT440 compared with placebo in healthy subjects and subjects with sickle cell disease (SCD).
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966